5-acetoxy-12H-benzophenothiazine | 93211-73-5

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 5-acetoxy-12H-benzophenothiazine
• 英文别名: 5-acetoxy-12H-benzo[a]phenothiazine；12H-benzo[a]phenothiazin-5-yl acetate
• CAS: 93211-73-5
• 化学式: C₁₈H₁₃NO₂S
• 分子量: 307.373
• InChiKey: PXKKPHXUVHLZHD-UHFFFAOYSA-N

物化性质

• 熔点：
  184-185 °C
• 沸点：
  525.8±39.0 °C(predicted)
• 密度：
  1.317±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

上下游信息

反应信息

• 作为反应物：
  描述：

  5-acetoxy-12H-benzophenothiazine 在 sodium hydroxide 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 1.58h， 生成 5-hydroxy-12H-benzophenothiazine 7-oxide
  参考文献：
  名称：

  First synthesis of sulfoxides and sulfones in the 3H-phenothiazin-3-one and 5H-benzo[a]phenothiazin-5-one ring systems. Addition reactions with nucleophiles

  摘要：

  DOI：

  10.1021/jo00227a012
• 作为产物：
  描述：

  苯并[a]吩噻嗪-5-酮 在 吡啶 、 sodium disulfite 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 5-acetoxy-12H-benzophenothiazine
  参考文献：
  名称：

  First synthesis of sulfoxides and sulfones in the 3H-phenothiazin-3-one and 5H-benzo[a]phenothiazin-5-one ring systems. Addition reactions with nucleophiles

  摘要：

  DOI：

  10.1021/jo00227a012

文献信息

• Phenothiazone derivatives and analogs
  申请人：Merck Frosst Canada, Inc.

  公开号：US04667032A1

  公开（公告）日：1987-05-19

  Phenothiazone derivatives and analogs thereof, pharmaceutical compositions and methods of treatment are disclosed. These compounds are useful as inhibitors of mammalian leukotriene biosynthesis. As such, these compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular disorders and inflammation.

  苯并噻唑衍生物及其类似物、药物组合物和治疗方法已被披露。这些化合物可用作哺乳动物白三烯生物合成的抑制剂。因此，这些化合物是治疗过敏症、哮喘、心血管疾病和炎症的有用治疗剂。
• Benzo[A]phenothiazines and hydro-derivatives
  申请人：Merck Frosst Canada, Inc.

  公开号：US04611056A1

  公开（公告）日：1986-09-09

  Pharmaceutical compositions containing a compound of Formula I: ##STR1## wherein X is O, S, SO or SO.sub.2 and R.sub.2, R.sub.3, R.sub.4 and R.sub.5 may be positioned anywhere on the structure, or a pharmaceutically-acceptable salt thereof and certain novel benzo[a]phenothiazines, which compositions and compounds are useful in treating allergic conditions, asthma, cardiovascular disorders, inflammation and pain and are useful as cytoprotective agents.

  含有Formula I化合物的药物组合物：其中X为O、S、SO或SO.sub.2，R.sub.2、R.sub.3、R.sub.4和R.sub.5可以位于结构的任何位置，或其药用盐，以及某些新型苯并[a]苯并噻嗪类化合物，这些组合物和化合物可用于治疗过敏症、哮喘、心血管疾病、炎症和疼痛，并可用作细胞保护剂。
• Benzo[a]phenothiazines and hydro-derivatives for inhibiting leukotriene
  申请人：Merck Frosst Canada, Inc.

  公开号：US04876246A1

  公开（公告）日：1989-10-24

  Pharmaceutical compositions containing a compound of Formula I: ##STR1## wherein X is O, S, SO or SO.sub.2 and R.sub.2, R.sub.3, R.sub.4 and R.sub.5 may be positioned anywhere on the structure, or a pharmaceutically-acceptable salt thereof and certain novel benzo[a]phenothiazines, which compositions and compounds are useful in treating allergic conditions, asthma, cardiovascular disorders, inflammation and pain and are useful as cytoprotective agents.

  含有公式I中化合物的药物组合物：其中X为O，S，SO或SO.sub.2，而R.sub.2，R.sub.3，R.sub.4和R.sub.5可以位于结构的任何位置，或其药学上可接受的盐和某些新型苯并[a]苯并噻吩，这些组合物和化合物用于治疗过敏性疾病，哮喘，心血管疾病，炎症和疼痛，并且作为细胞保护剂有用。
• Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0136893A2

  公开（公告）日：1985-04-10

  Pharmaceutical compositions contain a compound for the Formula or a pharmaceutically acceptable salt thereof. Certain compounds of Formula I are novel. Compounds of Formula I are useful in treating allergic conditions, asthma, cardrovascular disorders, inflammation and pain and are useful as cytoprotective agents. In Formula 1. X is O, S, SO or SO2; R, is H; C,-6 alkyl; C, -6 acyl; C1-6 aminoacyl; (C1-6 acyloxy)-(C1-6 alkyl); (C1-6 alkoxy)-(Cl-6 alkyl); benzoyl; substituted benzoyl in which the substitution in the phenyl ring (herein called "substituted as herein defined") is halogen, C1-3 alkyl, C1-3 alkoxy, CN, CF3, COOR6, OH, CH2COOR6 or (CH2)nNR8R9 where n is 0, 1 or 2; carbamoyl; CONHR7; COOR7; p-toluenesulfonyl; methane sulfonyl; or an acyl group such that R,-OH is an essential amino acid; each of R2, R3, R4 and R5, independently of the others, is hydrogen; C1-6 alkyl; C2-6 alkenyl; -(CHR6)pCOOR6, p being 0 or an integer from 1 to 4; or -(CH2)mM where m is 0 or an integer from 1 to 6 and M is (a) OR,s; (b) halogen; (c) CF3; (d) SR15; (e) phenyl or substituted phenyl as herein defined; (f) COOR6; (g) CO-R14; (h) tetrazolyl; (i) -NH-CO-R7; (j) -NR8R9; (k) -NHSO2R10 where R10 is OH, C1-6 alkyl, C1-6 alkoxy, or phenyl; (I) -COCH20H; (m) -SOR11 where R11 is C1-6 alkyl; phenyl; substituted phenyl as herein defined; (CH2)mCOOR6;CN; formyl or C1-4 perfluoroalkyl; (n) -CONR8R9; (o) -SO2NR8R9; (p) -SO2R13 where R13 is a hydrogen atom or a radical of the type defined for R11; (q) NO2; (r) O-CO-R14; (s) O-CO-NR8R9; (t) -CN; or (u) -OPO(OR6)2: each R6, independently of any other, is H, phenyl or C1-6 alkyl; each R7, independently of any other, is C1-6 alkyl, benzyl, phenyl or (C1-6 acyloxyl-(C1-6 alkyl); each R8 and each R9, independently of any other, is phenyl, substituted phenyl as herein defined, or C1-4 alkyl, or NR8R9 represents a heterocycloalkyl radical of 5 to 8 ring atoms; each R14, independently of any other, is H. (CH2)pCOOR6, C, 6 alkyl, C1-6 alkoxy, (C1-6 acyloxy)-(C1-6 alkoxy), phenyl, substituted phenyl as herein defined, or C, -6 aminoalkyl, or R14 is such that R14CO2H is an essential amino acid; R15 is H, (C1-6 alkoxy)-(C1-6 alkyl), (C, 6 acyloxyl-(C1-6 alkyl), C1-6 alkyl, benzyl, -(CH2)mCOOR6, CN, formyl, C1-4 perfluoroalkyl, CH2-R12 where R12 is C1-5 alkyldimethylamino or phenyl, phenyl, or substituted phenyl as herein defined; the broken lines in ring A represent optional double bonds; R2, R3, R4 and R5 may be positioned anywhere in the structure.

  药用组合物包含一种式化合物 或其药学上可接受的盐。式 I 的某些化合物是新型化合物。式 I 的化合物可用于治疗过敏性疾病、哮喘、心血管疾病、炎症和疼痛，并可用作细胞保护剂。 在式 1 中 X 是 O、S、SO 或 SO2； R，是 H；C,-6 烷基；C, -6酰基；C1-6氨基酰基；(C1-6酰氧基)-(C1-6烷基)；(C1-6烷氧基)-(Cl-6烷基)；苯甲酰基；取代的苯甲酰基，其中苯环中的取代基（此处称为 "如本文定义的取代基"）是卤素、C1-3烷基、C1-3烷氧基、CN、CF3、COOR6、OH、 COOR6 或 (CH2)nNR8R9 其中 n 是 0、1 或 2；氨基甲酰基；CONHR7；COOR7；对甲苯磺酸基；甲烷磺酰基；或 R,-OH 为必需氨基酸的酰基； R2、R3、R4 和 R5 中各自独立地为氢；C1-6 烷基；C2-6 烯基；-(CHR6)pCOOR6，p 为 0 或 1 至 4 的整数；或-( )mM，其中 m 为 0 或 1 至 6 的整数，M 为 (a) OR,s；(b) 卤素； (c) ； (d) SR15； (e) 本文定义的苯基或取代苯基； (f) COOR6； (g) CO-R14； (h) 四唑基； (i) -NH-CO-R7; (j) -NR8R9；(k) -NHSO2R10 其中 R10 为 OH、C1-6 烷基、C1-6 烷氧基或苯基； (I) -CO 0H; (m) -SOR11 其中 R11 为 C1-6 烷基；苯基；本文定义的取代苯基；( )mCOOR6; CN; 甲酰基或 C1-4 全氟烷基；(n) -CONR8R9； (o) -SO2NR8R9 ； (p) -SO2R13 其中 R13 是氢原子或 R11 所定义的基团类型； (q) NO2； (r) O-CO-R14； (s) O-CO-NR8R9； (t) -CN；或 (u) -OPO(OR6)2： 每个 R6（独立于任何其他物质）是 H、苯基或 C1-6 烷基； 每个 R7（独立于任何其他物质）是 C1-6 烷基、苄基、苯基或 (C1-6 acyloxyl-(C1-6 烷基)； 每个 R8 和每个 R9，各自独立地为苯基、本文定义的取代苯基或 C1-4 烷基，或 NR8R9 代表 5 至 8 个环原子的杂环烷基； ( )pCOOR6 是 H、( )pCOOR6、C, 6 烷基、C1-6 烷氧基、(C1-6 乙酰氧基)-(C1-6 烷氧基)、苯基、本文定义的取代苯基或 C, -6 氨基烷基，或 R14 是这样的 R14CO2H 是必需氨基酸； R15 是 H、(C1-6 烷氧基)-(C1-6 烷基)、(C, 6 乙酰氧基-(C1-6 烷基))、C1-6 烷基、苄基、-( )mCOOR6、CN、甲酰基、C1-4 全氟烷基、 -R12，其中 R12 是本文定义的 C1-5 烷基二甲基氨基或苯基、苯基或取代苯基； 环 A 中的断线代表可选的双键； R2、R3、R4 和 R5 可位于结构中的任何位置。
• Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition
  申请人：Merck & Co., Inc.

  公开号：EP0155623A2

  公开（公告）日：1985-09-25

  Lipoxygenase inhibitors are used as cytoprotective active ingredient in producing cytoprotective pharmaceutical compositions. Corresponding cytoprotective pharmaceutical compositions are prepared by incorporating into a pharmaceutical composition a lipoxygenase inhibitor in a cytoprotective active amount. The prepared cytoprotective therapeutic composition may be used to treat or prevent disease states such as erosive gastritis, erosive esophagitis, inflammatory bowel disease, and induced hemorrhagic gastric erosions such as those caused by indomethacin or ethanol. The lipoxygenase inhibitors induce cytoprotection via an unspecified mechanism.

  脂氧合酶抑制剂作为细胞保护活性成分可用于生产细胞保护药物组合物。相应的细胞保护药物组合物是通过在药物组合物中加入具有细胞保护活性量的脂氧合酶抑制剂来制备的。制备的细胞保护治疗组合物可用于治疗或预防疾病状态，如糜烂性胃炎、糜烂性食管炎、炎症性肠病和诱导性出血性胃糜烂，如由吲哚美辛或乙醇引起的胃糜烂。脂氧合酶抑制剂通过不明机制诱导细胞保护。